Symbols

Symbols

OCUL

OCUL

Ocular Therapeutix Stock Earns 81 RS Rating, Indicates Market Leadership

Monday Nov 10, 2025

RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Prospects

Beam Therapeutics' Q3 Results Attract Clear Street, Raises PT to $37

Friday Nov 07, 2025

Ocular Therapeutix CBO Namrata Sells 25,865 Shares at $10.74 on 2025-11-05

Ocular Therapeutix grants inducement awards to non-executive employee.

Wednesday Nov 05, 2025

Chardan Capital Reiterates Buy Recommendation for Ocular Therapeutix with 96.51% Upside Potential

Ocular Therapeutix: Chardan Capital maintains Buy, raises PT to $21.

Ocular Therapeutix (OCUL) Faces Ongoing Losses Amid Bullish Revenue Growth Expectations

Tuesday Nov 04, 2025

Ocular Therapeutix Exceeds Solar Trial Target, Seeks Broad Diabetic Retinopathy Label and Reports Strong Financial Position

Ocular Therapeutix Sets 2025 as Transformative Year with Advancements in Wet AMD Trials and Extended Cash Runway into 2028.

Ocular Therapeutix AXPAXLI Wet AMD Trial Hits Randomization Target, Topline Data in 1H 2027.

Ocular Therapeutix Achieves 555 Subject Randomization Target in SOL-R Trial for Wet AMD Treatment

Thursday Oct 30, 2025

Ocular Therapeutix: TD Cowen Maintains Buy Rating with $20 PT

Ocular Therapeutix (OCUL) Analysts See 82.93% Upside Potential

Ocular Therapeutix's 15min chart: KDJ Death Cross, bearish Marubozu signals.

Wednesday Oct 29, 2025

Ocular Therapeutix Price Target Boosted by 17.76% to $21.42

Tuesday Oct 28, 2025

Ocular Therapeutix to Host Conference Call on November 4, 2025.

Friday Oct 24, 2025

Ocular Therapeutix: Undervalued Biotech with Strong Growth Potential

Ocular Therapeutix's 15min Chart Triggers KDJ Death Cross, Bearish Marubozu Signal

Wednesday Oct 22, 2025

Ocular Therapeutix's 15min chart shows KDJ Death Cross and Bearish Marubozu.